tiprankstipranks
Affimed (GB:0HL9)
LSE:0HL9

Affimed (0HL9) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0HL9 Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Affimed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HL9 Stock 12 Months Forecast

There Are No Analyst Ratings for GB:0HL9 In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

0HL9 Financial Forecast

0HL9 Earnings Forecast

Next quarter’s earnings estimate for 0HL9 is -$1.45 with a range of -$1.71 to -$1.19. The previous quarter’s EPS was -$1.73. 0HL9 beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 34.62% of the time in the same period. In the last calendar year 0HL9 has Underperformed its overall industry.
Next quarter’s earnings estimate for 0HL9 is -$1.45 with a range of -$1.71 to -$1.19. The previous quarter’s EPS was -$1.73. 0HL9 beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 34.62% of the time in the same period. In the last calendar year 0HL9 has Underperformed its overall industry.

0HL9 Sales Forecast

Next quarter’s sales forecast for 0HL9 is $800.91K with a range of $800.91K to $800.91K. The previous quarter’s sales results were $2.13M. 0HL9 beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 46.91% of the time in the same period. In the last calendar year 0HL9 has Underperformed its overall industry.
Next quarter’s sales forecast for 0HL9 is $800.91K with a range of $800.91K to $800.91K. The previous quarter’s sales results were $2.13M. 0HL9 beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 46.91% of the time in the same period. In the last calendar year 0HL9 has Underperformed its overall industry.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright
$50.00
Buy
822.17%
Upside
Reiterated
12/14/23
Buy Rating Reaffirmed for Affimed as Promising Clinical Trials Propel Optimism
Leerink Partners
$50.00
Buy
822.17%
Upside
Reiterated
12/12/23
We were surprised and encouraged by the early positive signal with AFM24 (EGFR innate cell engager) + atezolizumab (atezo, anti-PDL1) in PD-1 relapsed / refractory, EGFRwt non-small cell lung cancer (NSCLC) and believe the stock may more positively reflect these data over time. In this very difficult setting where we expect little to no activity with atezo alone, the combination drove four responses (two confirmed), including a confirmed complete response (CR). Such activity is stand-out among immuno-oncology (IO)-only regimens in the setting. If confirmed in more patients in 2024, this signal warrants investment either in the r/r setting (if durability is also promising) or in combination with a cytotoxic (potentially an antibody drug conjugate [ADC]) and/or the r/r or 1L setting.
Wells Fargo
$30.00
Buy
453.30%
Upside
Assigned
11/14/23
Analysts Are Bullish on Top Healthcare Stocks: Syros Pharmaceuticals (SYRS), Affimed (AFMD)
Truist Financial
Buy
Reiterated
11/14/23
Truist Financial Reaffirms Their Buy Rating on Affimed (AFMD)
Wolfe Research
$60.00
Buy
1006.60%
Upside
Reiterated
08/10/23
Berenberg Bank Reaffirms Their Buy Rating on Affimed (AFMD)
Berenberg Bank
$60.00
Buy
1006.60%
Upside
Reiterated
05/24/23
Berenberg Bank Reaffirms Their Buy Rating on Affimed (AFMD)

Best Analysts Covering Affimed

Which Analyst Should I Follow If I Want to Buy GB:0HL9 and Sell After:
1 Month
Swayampakula RamakanthH.C. Wainwright
Success Rate
3/7 ratings generated profit
43%
Average Return
+0.09%
reiterated a buy rating 4 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +0.09% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Srikripa DevarakondaTruist Financial
Success Rate
2/7 ratings generated profit
29%
Average Return
-10.04%
reiterated a buy rating 5 months ago
Copying Srikripa Devarakonda's trades and holding each position for 3 Months would result in 28.57% of your transactions generating a profit, with an average return of -10.04% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Swayampakula RamakanthH.C. Wainwright
Success Rate
2/7 ratings generated profit
29%
Average Return
-14.94%
reiterated a buy rating 4 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -14.94% per trade.
2 Years
Swayampakula RamakanthH.C. Wainwright
Success Rate
2/7 ratings generated profit
29%
Average Return
-12.31%
reiterated a buy rating 4 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -12.31% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HL9 Analyst Recommendation Trends

Rating
Jun 23
Aug 23
Oct 23
Nov 23
Dec 23
Strong Buy
7
10
6
7
4
Buy
1
0
1
3
3
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
10
7
10
7
In the current month, 0HL9 has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0HL9 average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0HL9 Stock Forecast FAQ

What is GB:0HL9’s average 12-month price target, according to analysts?
Currently, no data Available
What is GB:0HL9’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for GB:0HL9, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Affimed a Buy, Sell or Hold?
      Currently, no data Available
      What is Affimed’s share price target?
      Currently, no data Available
      What do analysts say about Affimed?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Affimed?
      To buy shares of GB:0HL9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis